Product name40nm Gold Nanoparticles (1 OD)
40nm Gold Nanoparticles (1 OD) (ab269928) is an aqueous suspension of spherical metallic nanoparticles manufactured to the highest standard to ensure:
- Uniform spherical shape
- Narrow size distribution: 40nm ± 4nm, <10% CV
- Ultra high quality
- Batch to batch consistency
- High efficiency antibody binding for maximum sensitivity
- Available at high concentrations to simplify assay development.
This product is manufactured by Expedeon, an Abcam company. It was previously called 40nm Gold Nanoparticles (1 OD). Expedeon product code 201-0010 is the same as the 10 mL size of this product and code 201-0100 is the same as the 100 mL size.
Our colloidal Gold Nanoparticles are suspended in citrate buffer and are suitable for:
- Protein adsorption
- Oligonucleotide adsorption
- Surface modifications.
Narrow size distribution and consistent shape is important and preferable for most applications.
A consistent, spherical shape means that particles are less prone to aggregation, which can be a problem associated with gold nanoparticles. Furthermore uniform shape ensures consistent binding of antibodies, ensuring reliable assay results.
Each batch of 40nm colloidal gold undergoes TEM analysis to ensure all the requirements are met.
- Mean diameter 36–44nm
- SD <4nm
- CV% <10%
Storage instructionsShipped at Room Temperature. Store at +4°C. Do Not Freeze.
Storage bufferpH: 7
Constituent: 0.0058% Gold nanoparticles
Concentration information loading...
Electron microscopy (TEM) images of 40nm Gold Nanoparticles (1 OD) (ab269928). Note the consistency of size and shape.
Size distribution of 40nm Gold Nanoparticles (1 OD) (ab269928) displaying a narrow size distribution with a CV (standard deviation / diameter) of less than 10%.
UV-Vis spectrum of 40nm Gold Nanoparticles (1 OD) (ab269928).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab269928 has not yet been referenced specifically in any publications.